MDNAF · OTC · SIC 2834: Pharmaceutical Preparations
142
SEC Filings
$0.285
Close 2026-09-23
Business Summary
Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Its pipeline includes MDNA11, a beta-only IL-2 superkine being evaluated in the Phase 1/2 ABILITY Study, and BiSKIT candidates. The company also has IL-4 and IL-13 based Empowered Cytokine programs, including work on recurrent glioblastoma (rGBM). Medicenna has no approved products or product revenue and relies on external funding for research and development.
Look up MDNAF using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on MDNAF, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/MDNAF (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.